GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (NAS:HARP) » Definitions » Earnings per Share (Diluted)

Harpoon Therapeutics (Harpoon Therapeutics) Earnings per Share (Diluted) : $-8.76 (TTM As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Harpoon Therapeutics Earnings per Share (Diluted)?

Harpoon Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.46. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-8.76.

Harpoon Therapeutics's EPS (Basic) for the three months ended in Sep. 2023 was $-0.46. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-8.76.

Harpoon Therapeutics's EPS without NRI for the three months ended in Sep. 2023 was $-0.46. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-8.40.

During the past 3 years, the average EPS without NRIGrowth Rate was 7.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -6.50% per year.

During the past 7 years, Harpoon Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 7.30% per year. The lowest was -28.50% per year. And the median was -12.85% per year.


Harpoon Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Harpoon Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harpoon Therapeutics Earnings per Share (Diluted) Chart

Harpoon Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Earnings per Share (Diluted)
Get a 7-Day Free Trial -11.45 -25.60 -19.90 -36.20 -20.40

Harpoon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.52 -5.50 -3.10 0.30 -0.46

Competitive Comparison of Harpoon Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Harpoon Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harpoon Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harpoon Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Harpoon Therapeutics's PE Ratio falls into.



Harpoon Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Harpoon Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-67.731-0)/3.317
=-20.42

Harpoon Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2023 is calculated as

Diluted Earnings Per Share (Q: Sep. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-1.802-0)/3.948
=-0.46

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Harpoon Therapeutics  (NAS:HARP) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Harpoon Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Harpoon Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Harpoon Therapeutics (Harpoon Therapeutics) Business Description

Traded in Other Exchanges
Address
131 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.
Executives
Vijay K Lathi 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 2500 SAND HILL ROAD, SUITE 203, MENLO PARK CA 94025
Luke Nathaniel Walker officer: Chief Medical Officer C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Frank J Lanza officer: Principal Fin. & Acctng Ofc. C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lauren P Silvernail director 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Georgia Erbez officer: Chief Financial Officer 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Oncology Impact Fund (cayman) Management L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Alan Colowick director C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
New Leaf Bpo Associates Ii, L.p. 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
Ronald Hunt director, 10 percent owner C/O CREDIT SUISSE 1ST BOSTON PRV EQY, 11 MADISON AVENUE, NEW YORK NY 10010
New Leaf Bpo Management Ii, L.l.c 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
New Leaf Ventures Iii, L.p. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Associates Iii, L.p. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Management Iii, L.l.c. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Biopharma Opportunities Ii, L.p. 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170